Survival Comparison between Hemodialysis and Peritoneal Dialysis Based on Matched Doses of Delivered Therapy

Article Figures & Data

Table 1.

Population descriptive statistics^a

Parameter	RKDP (HD)	CANUSA(PD)
^a RKDP, Regional Kidney Disease Program; HD, hemodialysis; CANUSA, Canadian/United States prospective trial; PD, peritoneal dialysis; DM, diabetes mellitus; CVD, cardiovascular disease; RRF, residual renal function.
n	968	680
Mean age (yr)	60.1	54.3
DM as primary renal diagnosis (%)	40%	30%
CVD history (%)	60%	36%
Mean serum albumin	35.3 g/L	34.9 g/L
Mean total therapy Kt/V (dialytic and RRF combined)	1.59(per HD)	2.38(per wk at baseline)
		1.99(per wk at 24 mo)

Table 3.

Results of the Cox analysis of relative risksfor hemodialysis

Risk^a	Relative Risk	P^b
^a DM, diabetes mellitus; CVD, cardiovascular disease.
^b P value is compared with the reference group.
Age <45 y	1.00	Reference group
Age 45–60 y	1.57	0.13
Age >60 y	3.48	0.0001
DM (primary disease)	1.26	0.11
CVD history	1.20	0.13
Serum albumin (increase of 1 g/L)	0.83	0.0001
Kt/V (increase of 0.1 per session)	0.93	0.002

Table 4.

Results of the Cox analysis of relative risksfor hemodialysis

Risk^a	Relative Risk	P^b
^a DM, diabetes mellitus; CVD, cardiovascular disease.
^b P value is compared with the reference group.
Age <45 y	1.00	Reference group
Age 45–60 y	1.50	0.32
Age >60 y	2.40	0.02
DM (primary disease)	1.10	0.60
CVD history	2.40	0.0002
Serum albumin (increase of 1 g/L)	0.93	0.001
Kt/V (increase of 0.1 per week)	0.92	0.0009

Table 5.

Predicted 2-yr percent survival (mean ± SEM) versus Kt/V: Age >61 yr, diabetes mellitus as primary disease, cardiovascular disease present

(Kt/V)_HD^a	(Survival)_HD	(Survival)_PD	(Kt/V)_PD^a
^a (Kt/V)_HD and (Kt/V)_PD were matched on the basis of the peak concentration hypothesis.
0.84	58 ± 6	48 ± 9	1.6
0.95	60 ± 5	51 ± 9	1.7
1.07	62 ± 5	54 ± 8	1.8
1.20	65 ± 4	56 ± 8	1.9
1.35	68 ± 3	59 ± 7	2.0
1.52	71 ± 3	61 ± 7	2.1
1.70	73 ± 3	64 ± 7	2.2

Table 6.

Predicted 2-yr percent survival (mean ± SEM) versus Kt/V: Age >61 yr, diabetes mellitus as primary disease, cardiovascular disease absent

(Kt/V)_HD^a	(Survival)_HD	(Survival)_PD	(Kt/V)_PD^a
^a (Kt/V)_HD and (Kt/V)_PD were matched on the basis of the peak concentration hypothesis.
0.84	66 ± 8	74 ± 7	1.6
0.95	68 ± 7	75 ± 6	1.7
1.07	70 ± 6	77 ± 6	1.8
1.20	72 ± 6	78 ± 6	1.9
1.35	75 ± 5	80 ± 5	2.0
1.52	77 ± 4	81 ± 5	2.1
1.70	80 ± 4	83 ± 5	2.2

Table 7.

Predicted 2-yr percent survival (mean ± SEM) versus Kt/V: Age 46–60 yr, diabetes mellitus as primary disease, cardiovascular disease absent

(Kt/V)_HD^a	(Survival)_HD	(Survival)_PD	(Kt/V)_PD^a
^a (Kt/V)_HD and (Kt/V)_PD were matched on the basis of the peak concentration hypothesis.
0.84	83 ± 4	83 ± 5	1.6
0.95	84 ± 4	84 ± 5	1.7
1.07	85 ± 3	85 ± 4	1.8
1.20	86 ± 3	86 ± 4	1.9
1.35	88 ± 3	87 ± 4	2.0
1.52	89 ± 2	88 ± 3	2.1
1.70	90 ± 2	89 ± 3	2.2

Table 8.

Predicted 2-yr percent survival (mean ± SEM) versus Kt/V: Age ≤45 yr, diabetes mellitus not primary disease, cardiovascular disease absent

(Kt/V)_HD^a	(Survival)_HD	(Survival)_PD	(Kt/V)_PD^a
^a (Kt/V)_HD and (Kt/V)_PD were matched on the basis of the peak concentration hypothesis.
0.84	91 ± 3	95 ± 1	1.6
0.95	91 ± 3	90 ± 3	1.7
1.07	92 ± 2	91 ± 3	1.8
1.20	93 ± 2	91 ± 3	1.9
1.35	93 ± 2	87 ± 4	2.0
1.52	94 ± 2	93 ± 3	2.1
1.70	95 ± 1	93 ± 2	2.2